Mobile

A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation

Update Il y a 4 ans
Reference: EUCTR2004-000244-24

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of the study is to model the dose response of UK-390,957 at week 8 and to define the least effective dose in the ≤2 minutes population, based on Intervaginal Ejaculatory Latency Time as the primary endpoint.

Inclusion criteria

  • premature ejaculation

Links